Fabian A Mendoza

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9048971/publications.pdf

Version: 2024-02-01

623574 752573 22 816 14 20 citations g-index h-index papers 22 22 22 1080 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Progressive multifocal fibrosing neuropathy: description of a novel disease. Acta Neuropathologica Communications, 2022, 10, 34.	2.4	O
2	Tyrosine kinases in the pathogenesis of tissue fibrosis in systemic sclerosis and potential therapeutic role of their inhibition. Translational Research, 2021, 231, 139-158.	2.2	20
3	A comprehensive framework for navigating patient care in systemic sclerosis: A global response to the need for improving the practice of diagnostic and preventive strategies in SSc. Best Practice and Research in Clinical Rheumatology, 2021, 35, 101707.	1.4	22
4	Serine-Threonine Kinase inhibition as antifibrotic therapy: TGF- \hat{l}^2 and ROCK inhibitors. Rheumatology, 2021, , .	0.9	1
5	Increased expression of interferon regulated and antiviral response genes in CD31+/CD102+ lung microvascular endothelial cells from systemic sclerosis patients with end-stage interstitial lung disease. Clinical and Experimental Rheumatology, 2021, 39, 1298-1306.	0.4	5
6	Recurrence of progressive skin involvement following discontinuation or dose reduction of Mycophenolate Mofetil treatment in patients with diffuse Systemic Sclerosis. Seminars in Arthritis and Rheumatism, 2020, 50, 135-139.	1.6	12
7	Health Assessment Questionnaire-Disability Index (HAQ-DI) use in modelling disease progression in diffuse cutaneous systemic sclerosis: an analysis from the EUSTAR database. Arthritis Research and Therapy, 2020, 22, 257.	1.6	20
8	Primary osteoporosis in men: an unmet medical need. Fertility and Sterility, 2019, 112, 791-798.	0.5	9
9	Role of microRNA in the pathogenesis of systemic sclerosis tissue fibrosis and vasculopathy. Autoimmunity Reviews, 2019, 18, 102396.	2.5	50
10	Abrogation of transforming growth factor- \hat{l}^2 -induced tissue fibrosis in mice with a global genetic deletion of Nox4. Laboratory Investigation, 2019, 99, 470-482.	1.7	19
11	Endothelial cell-specific activation of transforming growth factor- \hat{l}^2 signaling in mice induces cutaneous, visceral, and microvascular fibrosis. Laboratory Investigation, 2017, 97, 806-818.	1.7	20
12	Endothelial Cells Expressing Endothelial and Mesenchymal Cell Gene Products in Lung Tissue From Patients With Systemic Sclerosis–Associated Interstitial Lung Disease. Arthritis and Rheumatology, 2016, 68, 210-217.	2.9	91
13	Role of muscarinic-3 receptor antibody in systemic sclerosis: correlation with disease duration and effects of IVIG. American Journal of Physiology - Renal Physiology, 2016, 310, G1052-G1060.	1.6	49
14	Treatment of rapidly progressive systemic sclerosis: current and futures perspectives. Expert Opinion on Orphan Drugs, 2016, 4, 31-47.	0.5	20
15	Stimulation of Transforming Growth Factor- \hat{l}^2 1-Induced Endothelial-To-Mesenchymal Transition and Tissue Fibrosis by Endothelin-1 (ET-1): A Novel Profibrotic Effect of ET-1. PLoS ONE, 2016, 11, e0161988.	1.1	76
16	Severe Eosinophilic Syndrome Associated with the Use of Probiotic Supplements: A New Entity?. Case Reports in Rheumatology, 2012, 2012, 1-3.	0.2	5
17	A Prospective Observational Study of Mycophenolate Mofetil Treatment in Progressive Diffuse Cutaneous Systemic Sclerosis of Recent Onset. Journal of Rheumatology, 2012, 39, 1241-1247.	1.0	76
18	Effects of Scleroderma Antibodies and Pooled Human Immunoglobulin on Anal Sphincter and Colonic Smooth Muscle Function. Gastroenterology, 2012, 143, 1308-1318.	0.6	38

#	Article	IF	CITATIONS
19	Systemic sclerosis disease modification clinical trials design: Quo vadis?. Arthritis Care and Research, 2012, 64, n/a-n/a.	1.5	7
20	Systemic Sclerosis Mortality in the United States. Journal of Clinical Rheumatology, 2007, 13, 187-192.	0.5	35
21	Description of 12 Cases of Nephrogenic Fibrosing Dermopathy and Review of the Literature. Seminars in Arthritis and Rheumatism, 2006, 35, 238-249.	1.6	241
22	Nephrogenic systemic fibrosis–related pulmonary restriction: An under-appreciated manifestation potentially reversible with imatinib therapy. Journal of Scleroderma and Related Disorders, 0, , 239719832210882.	1.0	0